(E)-3-(2-Butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide (E)-3-(2-丁基-1-(2-(二乙氨基)乙基)-1H-苯并[d]咪唑-5-基)-N-羟基丙烯酰胺
CAS 929016-96-6 MFCD029016966
化学结构图
SMILES: CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC
化学属性
| Mol. Weight | 358.4778 |
|---|---|
| Mol. Formula | C20H30N4O2 |
| Appearance | white solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| CAS Number | 929016-96-6 |
|---|---|
| Chemical Name | (E)-3-(2-Butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide |
| Synonym | ######## SB939; SB 939; SC-939; Pracinostat. |
| Chemical Name Translation | (E)-3-(2-丁基-1-(2-(二乙氨基)乙基)-1H-苯并[d]咪唑-5-基)-N-羟基丙烯酰胺 |
| Formula | C20H30N4O2 |
| IUPAC Name | (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide |
| InChIKey | JHDKZFFAIZKUCU-ZRDIBKRKSA-N |
| InChI | InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+ |
| Canonical SMILES | O=C(NO)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Amines
- Aromatics
- Heterocycles
- Inhibitors
- Pharmaceuticals
- Intermediates & Fine Chemicals
产品应用
- Pracinostat, also known as SB939, is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which may result in the accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; the tumor suppressor protein-mediated inhibition of tumor cell division; and, finally, the induction of tumor cell apoptosis. In March 2014, pracinostat has granted Orphan Drug for acute myelocytic leukemia (AML) and for the treatment of T-cell lymphoma by the Food and Drug Administration.
相关文献及参考
- Novotny-Diermayr, V. et al.: Mol. Cancer Therap., 9, 642 (2010); Razak, A.R.A. et al.: Br. J. Cancer, 104, 756 (2011); Novotny-Diermayr, V. et al.: Mol. Cancer Therap., 10, 1207 (2011);
京ICP备2020036287号